Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

RARITAN, N.J., May 18, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson& Johnson announced today results from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab (JNJ-6372) in the treatment...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials